



Article

Pterostilbene Induces Apoptosis from Endoplasmic Reticulum Stress Synergistically with Anticancer Drugs That Deposit Iron in Mitochondria

Yukiko Nishiguch ¹, Rina Fujiwara-Tani ^{1,*}, Shota Nukaga ¹, Ryoichi Nishida ¹, Ayaka Ikemoto ¹, Rika Sasaki ¹, Shiori Mori ¹, Ruiko Ogata ¹, Shingo Kishi ^{1,2}, Yudai Hojo ³, Hisashi Shinohara ³, Masayuki Sho ⁴ and Hiroki Kuniyasu ^{1,*} 

¹ Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan; yukko10219102@yahoo.co.jp (Y.N.); shota.nukaga@gmail.com (S.N.); g.m_r1@outlook.jp (R.N.); a.ikemoto.0916@gmail.com (A.I.); rika0st1113v726296v@icloud.com (R.S.); m.0310.s.h5@gmail.com (S.M.); pkuma.og824@gmail.com (R.O.); nmu6429@yahoo.co.jp (S.K.)

² Pathology Laboratory, Research Institute, Tokushukai Nozaki Hospital, 2-10-50 Tanigawa, Daito 574-0074, Osaka, Japan

³ Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya 663-8501, Hyogo, Japan; yudaihojo@outlook.com (Y.H.); shinohara@hyo-med.ac.jp (H.S.)

⁴ Department of Surgery, Nara Medical University, Kashihara 634-8522, Nara, Japan; m-sho@naramed-u.ac.jp

* Correspondence: rina_fuji@naramed-u.ac.jp (R.F.-T.); cooninh@zb4.so-net.ne.jp (H.K.); Tel.: +81-744-22-3051 (R.F.-T. & H.K.); Fax: +81-744-25-7308 (R.F.-T. & H.K.)

Abstract: Anticancer agents are playing an increasing role in the treatment of gastric cancer (GC); however, novel anticancer agents have not been fully developed. Therefore, it is important to investigate compounds that improve sensitivity to the existing anticancer drugs. We have reported that pterostilbene (PTE), a plant stilbene, enhances the antitumor effect of low doses of sunitinib in gastric cancer cells accumulating mitochondrial iron (II) (mtFe) at low doses. In this study, we investigated the relationship between the mtFe deposition and the synergistic effect of PTE and different anticancer drugs. For this study, we used 5-fluorouracil (5FU), cisplatin (CPPD), and lapatinib (LAP), which are frequently used in the treatment of GC, and doxorubicin (DOX), which is known to deposit mtFe. A combination of low-dose PTE and these drugs suppressed the expression of PDZ domain-containing 8 (PDZD8) and increased mtFe accumulation and mitochondrial H₂O₂. Consequently, reactive oxygen species-associated hypoxia inducible factor-1 α activation induced endoplasmic reticulum stress and led to apoptosis, but not ferroptosis. In contrast, 5FU and CDDP did not show the same changes as those observed with PTE and DOX or LAP, and there was no synergistic effect with PTE. These results indicate that the combination of PTE with iron-accumulating anticancer drugs exhibits a strong synergistic effect. These findings would help in developing novel therapeutic strategies for GC. However, further clinical investigations are required.

Keywords: pterostilbene; PDZD8; mitochondria; MAM; ER stress



Citation: Nishiguch, Y.; Fujiwara-Tani, R.; Nukaga, S.; Nishida, R.; Ikemoto, A.; Sasaki, R.; Mori, S.; Ogata, R.; Kishi, S.; Hojo, Y.; et al. Pterostilbene Induces Apoptosis from Endoplasmic Reticulum Stress Synergistically with Anticancer Drugs That Deposit Iron in Mitochondria. *Int. J. Mol. Sci.* **2024**, *25*, 2611. <https://doi.org/10.3390/ijms25052611>

Academic Editor: Nam Deuk Kim

Received: 27 December 2023

Revised: 21 February 2024

Accepted: 22 February 2024

Published: 23 February 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Gastric cancer (GC) is currently the third and second leading cause of cancer-related death in Japan and worldwide, respectively [1,2]. Although the overall 5-year survival rate for this disease is 73.1% [3], the prognosis of patients with advanced GC remains poor, with the 5-year survival rate for stage IV cases being only 7.3% [3]. Recently, the benefits of using multidisciplinary treatment including major chemotherapeutic agents, such as cisplatin (CDDP), 5-fluorouracil (5FU), and taxanes, for such advanced cases have been highlighted [4]. Combination therapy in cancer treatment is the use of different drugs target cancer cells through multiple mechanisms. This approach offers several advantages in the management of cancer. Increased therapeutic efficacy, reduced drug

resistance, synergistic effects, minimized toxicity, overcoming target heterogeneity, and optimization of personalized therapy are some of the benefits of combination therapy. Therefore, the development of new anticancer drugs and new combination therapies will play an important role in cancer treatment [5].

The currently recommended molecular targeted therapy for GC is trastuzumab, which targets human epidermal growth factor receptor 2 (HER2) [4]. The survival rate of patients with HER2-positive GC is 22%, and trastuzumab can extend their survival [6]. However, the frequency of HER2-positive GC is less than 20% [7]. Therefore, there is a need for new molecular targeted therapies and for developing novel methods to sensitize tumors to the existing anticancer drugs.

Pterostilbene (PTE) is an abundant dietary nutrient in blueberries [8]. PTE inhibits cancer cell proliferation in a concentration-dependent manner, lowers mitochondrial membrane potential, and induces cell apoptosis [9,10]. We previously reported that PTE suppresses cancer stem cell activity [11]. Additionally, PTE shows synergistic antitumor effects against GC cell lines when used in combination with sunitinib (SUN) [12]. SUN suppresses the expression of PDZ domain-containing 8 (PDZD8), resulting in the deposition of mitochondrial iron (II) (mtFe). Iron influences cancer cell survival and proliferation through a variety of cellular processes: cell proliferation, energy metabolism, angiogenesis, oxidative stress, and immune response [13]. In particular, mitochondrial iron, as an iron–sulfur complex, is essential for energy production and other processes, while it is involved in cell death through ferroptosis [14]. In this work, the significance of mitochondrial iron deposition was also studied.

In this study, we aimed to investigate the synergistic effects of the combination of PTE with 5FU, CDDP, and LAP, which are frequently used to treat GC, and doxorubicin (DOX), which is known to affect mtFe deposition [15], on mtFe deposition in GC.

2. Results

2.1. Effect of High-Dose PTE on GC Cell Lines

First, we investigated the effect of PTE on GC cell lines (Figure 1A). A concentration-dependent inhibition of cell proliferation was observed. Thereafter, we conducted studies separately for high-dose PTE (PTE-H, 200 μ M) and low-dose PTE (PTE-L, 10 μ M). PTE-H inhibited the growth of both TMK1 and MKN74 GC cells by approximately 40%. PTE-H-induced cell death was investigated using various cell death inhibitors (Figure 1B), including ZVAD (apoptosis), ferrostatin (FER), deferoxamine (DFO) (ferroptosis), N-acetylcysteine (NAC, antioxidant), and 4-phenylbutyric acid (4PBA, endoplasmic reticulum [ER] stress). Cell death inhibitor assays showed that cell death was rescued by ZVAC, but not by FER, DFO, NAC, or 4PBA. In PTE-H cells, poly[ADP-ribose] polymerase (PARP) cleavage was observed, confirming apoptosis (Figure 1C). In terms of apoptosis-related gene expression, PTE-H treatment decreased *BCL2* expression and increased *BAX* expression (Figure 1D).

2.2. Relationship of Accumulation of mtFe with Anticancer Drugs and Sensitizing Effects of PTE

In a previous study, an increased synergistic antitumor effect was observed between SUN and PTE, which involved mtFe deposition [11]. Therefore, we investigated the effects of mtFe deposition on anticancer drugs using DOX, LAP, 5FU, and CDDP (Figure 2A). DOX and LAP increased mtFe, whereas 5FU and CDDP did not.




Figure 1. Effect of PTE-H in GC cells. (A) Effect of PTE on cell growth in GC cell lines, TMK1, and MKN74. (B) Cell death inhibitor assay. Cells were treated with PTE-H (200 μM) for 48 h with or without cell inhibitors. * $p < 0.05$ vs. all other groups. (C) PARP cleavage by PTE-H. (D) Effect of PTE-H on expression of *BCL2* and *BAX*. Error bar, standard deviation from three independent trials. * Significance was calculated using Tukey methods. GC, gastric cancer; PTE, pterostilbene; PTE-H, high-dose PTE; *BCL2*, B-cell lymphoma 2 gene; *BAX*, BCL-2-associated X protein gene; C, control; FER, ferrostaline-1; DFO, deferoxamine; NAC, N-acetyl-L-cysteine; ZVAD, Z-VAD-FMK; 4PBA, 4-phenylbutyric acid; PARP, poly ADP-ribose polymerase.

Next, we investigated the growth-inhibiting effects of the four anticancer drugs on the human GC cell lines TMK1 and MKN74 (Figure 2B). A concentration-dependent inhibition of cell proliferation was observed in both cell lines after treatment with each individual anticancer drug. In subsequent studies, a concentration equivalent to IC_{20} was used. Next, we investigated the combined effects of the four anticancer drugs at IC_{20} and a low concentration of PTE (PTE-L, 10 μM) (Figure 2C). In all GC cells, the combination of PTE-L and DOX or LAP exhibited a synergistic inhibitory effect on cell proliferation, whereas no additive inhibitory effect was observed with 5FU and CDDP. In contrast, a combination of PTE-H (200 μM) and the four anticancer drugs at IC_{20} showed additive growth inhibition in all cells (Figure 2D).

2.3. Effect of Combined Use of PTE-L and mtFe-Depositing Anticancer Drugs on Mitochondria

To investigate the effects of the combined use of PTE-L, DOX, and LAP on mitochondria, TMK1 and MKN74 GC cells were treated (Figure 3). Increased H_2O_2 levels were observed in both cell lines (Figure 3A). In contrast, no changes were observed in mitochondrial membrane potential or mitochondrial mass, even when PTE-L and anticancer drugs were combined (Figure 3B,C).




Figure 2. Accumulation of mtFe and PTE-L in GC cells. (A) Accumulation of mtFe in GC cells treated with PTE-L (10 μM) for 48 h. Scale bar, 50 μm. (Right) Semi-quantification of mtFe. * $p < 0.05$ vs. C. (B) Sensitivity to anti-cancer drugs: DOX, LAP, 5FU, CDDP. (C) Effect of concurrent treatment with anti-cancer drugs (IC₂₀) and PTE-L. * $p < 0.05$ vs. C, $p < 0.05$ vs. DOX+PTE, or ** $p < 0.05$ vs. LAP+PTE. (D) Effect of concurrent treatment with anti-cancer drugs (IC₂₀) and PTE-H (200 μM). * $p < 0.05$ vs. PTE 0. Error bar, standard deviation from three independent trials. *,** Significance was calculated using ANOVA. GC, gastric cancer; PTE, pterostilbene; PTE-H, high-dose PTE; PTE-L, low-dose PTE; C., control; mtFe, mitochondrial iron (II); DOX, doxorubicin; LAP, lapatinib; 5FU, 5-fluorouracil; CDDP, cisplatin; IC, inhibitory concentration.




Figure 3. Effect of concurrent treatment with PTE-L and DOX or LAP. GC cells were treated with PTE-L (10 μ M) and DOX or LAP (IC₂₀) for 48 h. (A) Mth₂O₂, (B) mitochondrial membrane potential determined based on TMRE. (C) MV based on mitogreen (right) semi-quantification of the fluorescence intensity. Scale bar, 50 μ m. * $p < 0.05$ vs. C, ** $p < 0.05$; DOX vs. DOX+PTE, or ** $p < 0.05$; LAP vs. LAP+PTE. ***, Significance was calculated using ANOVA with Bonferroni correction. Error bar, standard deviation from three independent trials. GC, gastric cancer; PTE, pterostilbene; PTE-H, high-dose PTE; PTE-L, low-dose PTE; C, control; DOX, doxorubicin; LAP, lapatinib; IC, inhibitory concentration; Mth₂O₂, mitochondrial H₂O₂; TMRE, tetramethylrhodamine ethyl ester; MV, mitochondrial volume.

2.4. Cell Death Due to the Combination of PTE-L and mtFe-Depositing Anticancer Drugs

As mentioned above, a synergistic effect of low-concentration PTE on DOX and LAP, which have mtFe deposition effects, was observed. Therefore, we performed a cell death inhibitor assay on cells treated with these drugs in combination with PTE-L (Figure 4A). The synergistic effect of DOX or LAP at IC₂₀ with PTE-L on cell death was not restored by FER or DFO. In contrast, approximately 90% recovery was observed with ZVAD and NAC, and complete recovery was observed with 4-PBA, the ER stress inhibitor.




Figure 4. Cell death in GC cells treated with a combination of PTE-L and DOX or LAP. (A) Cell death inhibitor assay in GC cells exposed to concurrent treatment with PTE-L and DOX (IC₂₀) (left) or PTE-L and LAP (IC₂₀) (right) * *p* < 0.05 vs. C. (B) ER stress-associated gene expression and PARP cleavage. (C) Expression of *BCL2* and *BAX*. (D) Effect of *CHOP* knockdown on cell death caused by concurrent treatment with PTE-L and DOX (left) or LAP (right). * *p* < 0.05 vs. C (siC), ** *p* < 0.05; DOX+PTE vs. DOX/siC or DOX+PTE-L/siCHOP (left), or ** *p* < 0.05; LAP+PTE-L vs. LAP/siC or LAP+PTE-L/siCHOP (right). Error bar, standard deviation from three independent trials. *,** Significance was calculated using ANOVA with Bonferroni correction.

GC, gastric cancer; PTE, pterostilbene; PTE-L, low-dose PTE; C, control; DOX, doxorubicin; LAP, lapatinib; IC, inhibitory concentration; ER, endoplasmic reticulum; GADD45, growth arrest and DNA damage inducible 45; CHOP, CCAAT/enhancer-binding protein homologous protein; PARP, poly ADP-ribose polymerase; *BCL2*, B cell lymphoma 2; *BAX*, BCL-2-associated X protein; C, control; FER, ferrostatine-1; DFO, deferoxamine; NAC, N-acetyl-L-cysteine; ZVAD, Z-VAD-FMK; 4PBA, 4-phenylbutyric acid; siC, control small interfering RNA; siCHOP, small interfering RNA for *CHOP*.

Consequently, we investigated the expression of growth arrest and DNA damage-inducible (*GADD45*) and CCAAT/enhancer-binding protein homologous protein (*CHOP*) genes to confirm that the synergistic effect was due to ER stress (Figure 4B). The expression of both genes was increased by the combination of anticancer drugs and PTE-L.

Furthermore, PARP cleavage was not observed with DOX or LAP (IC₂₀) alone, but was observed when these drugs were combined with PTE-L. This combination treatment decreased *BCL2* expression and increased *BAX* expression (Figure 4C). In contrast, *CHOP*-knockdown suppressed the cell death caused by the combination of DOX or LAP and PTE-L (Figure 4D). These results suggested that the combination of PTE-L and mtFe-depositing anticancer drugs induced apoptosis in cancer cells in response to ER stress.

2.5. Synergistic Effect of PTE and Anticancer Drugs on mtFe Deposition

Next, the mechanism of mtFe deposition in GC cells by DOX and LAP was examined. We previously reported that PTE reduces PDZD8, a protein in MAM [11]. Therefore, we investigated the effects of the four anticancer drugs on PDZD8 expression (Figure 5A). PDZD8 expression was decreased by DOX and LAP (mtFe-depositing drugs), whereas no change was observed with 5FU and CDDP (mtFe-non-depositing drugs). Next, we investigated the expression of mitochondrial protein containing the Asn-Glu-Glu-Thr (NEET) sequence (mitoNEET; mtNEET) and that of the ATP-binding cassette subfamily B member 8 (*ABCB8*), which bind to PDZD8 and are involved in iron transport. In both cases, the levels of PDZD8-binding proteins decreased with the DOX and LAP treatment, whereas no changes were observed with the 5FU and CDDP treatment (Figure 5A). Furthermore, we examined changes in the mRNA levels of *PDZD8*, *mtNEET*, and *ABCB8* when DOX and LAP were used alone or in combination with PTE-L (Figure 5B). The expression of *PDZD8*, *mtNEET*, and *ABCB8* was decreased by treatment with DOX, LAP, and PTE-L alone, and was further decreased when each drug was combined with PTE-L. mtFe accumulation and apoptosis were increased by treatment with DOX, LAP, and PTE-L alone and were further increased when each drug was combined with PTE-L (Figure 5C,D). In contrast, mitochondrial lipid peroxidation (mt-4HNE) did not change with treatment with DOX, LAP, or PTE-L alone, or when the drugs were combined with PTE-L (Figure 5E). The expression of glutathione peroxidase (GPX)-4 protein, which plays an important role in mitochondrial redox, was increased after treatment with DOX, LAP, and PTE-L alone, and was further increased when each drug was combined with PTE-L (Figure 5F).




Figure 5. MAM in GC cells treated with PTE-L and DOX or LAP. (A) Expression of PDZD8 and PDZD8-associated mtNEET and ABCB8. (B) Expression of MAM-associated genes. (C–F) Effect of concurrent treatment with PTE-L and DOX or LAP (IC_{20}) on mtFe, (C), apoptosis (D), mt-HNE4, (E) and mitochondrial GPX4 expression (F). * $p < 0.05$ vs. C (PTE–), ** $p < 0.05$ vs. DOX (PTE–), † $p < 0.05$ vs. LAP (PTE–). Error bar, standard deviation from three independent trials. ***,† Significance was calculated using ANOVA with Bonferroni correction. GC, gastric cancer; PTE, pterostilbene; PTE-L, low-dose PTE; C, control; DOX, doxorubicin; LAP, lapatinib; 5FU, 5-fluorouracil; CDDP, cisplatin; IC, inhibitory concentration; C, con; PDZD8, PDZ domain-containing 8; mtNEET, mitochondrial protein containing Asn–Glu–Glu–Thr (NEET) sequence; ABCB8, ATP-binding cassette subfamily B member 8; MAM, mitochondria-associated endoplasmic reticulum membrane; CB, Coomassie blue; IP, immunoprecipitation; mtFe, mitochondrial iron (II); mt-HNE4, mitochondrial hydroxynonenal-4; GPX4, glutathione peroxidase 4.

Next, factors linking endoplasmic reticulum stress and apoptosis were examined. No obvious changes were observed in the RNA expression of hypoxia-inducible factor-1 α (HIF1 α) and CHOP after treatment with DOX, LAP, and PTE-L alone, but their expression

levels increased upon treatment with the combination of each drug with PTE-L (Figure 6A). The increase in *CHOP* expression caused by the combination of DOX, LAP, and PTE-L was abolished by HIF1 α inhibition (Figure 6B). HIF1 α inhibition also suppressed apoptosis induced by the combination of anticancer drugs with PTE-L (Figure 6C). Furthermore, the inhibition of RNA-dependent protein kinase (PKR)-like ER kinase (PERK), an ER stress sensor related to the MAM, [16] also suppressed apoptosis induced by the combination of anticancer drugs with PTE-L (Figure 6D).




Figure 6. ER stress in GC cells treated with PTE-L and DOX or LAP. (A) Expression of ER stress-associated genes. (B,C) Effect of HIF1 α inhibitor on *CHOP* expression (B) and apoptosis (C). * $p < 0.05$; HIF1-I(−) vs. HIF1-I(+). (D) Effect of PERK inhibitor on apoptosis. * $p < 0.05$; PERK1-I(−) vs. PERK1-I(+). Error bar, standard deviation from three independent trials. * Significance was calculated using ANOVA with Bonferroni correction. GC, gastric cancer; PTE, pterostilbene; PTE-L, low-dose PTE; C, control; DOX, doxorubicin; LAP, lapatinib; IC, inhibitory concentration; C, con; PDZD8, PDZ domain-containing 8; mtNEET, mitochondrial protein containing Asn–Glu–Glu–Thr (NEET) sequence; ABCB8, ATP-binding cassette subfamily B member 8; HIF, hypoxia-inducible factor; mtFe, mitochondrial iron (II); mt-HNE4, mitochondrial hydroxynonenal-4; GPX4, glutathione peroxidase 4.

These results indicate that DOX, LAP, and PTE-L increased mtFe by suppressing the expression of PDZD8 and of the iron transporters recruited to PDZD8, i.e., mtNEET and ABCB8. Consequently, mitochondrial reactive oxygen species (ROS) levels increased, which increased HIF1 α expression, which further induced ER stress as well as apoptosis.

2.6. Effect of Combination of PTE-L and Anticancer Drugs in Mouse Subcutaneous Tumor Model

Finally, the effect of the combination of PTE and anticancer drugs was examined in vivo. TMK1 cells were subcutaneously inoculated into nude mice and mtFe-depositing LAP or non-mtFe-depositing CDDP was administered (Figure 7A). The synergistic effect of PTE-L and LAP resulted in a greater reduction in tumor growth than that achieved with LAP alone, whereas the combination of CDDP and PTE-L did not have any effect on tumor

growth (Figure 7B). When the levels of CHOP, H₂O₂, HIF1 α , and cleaved cytokeratin 18 (C-CK18, an apoptosis marker) were measured in subcutaneous tumors, CHOP, HIF1 α , and C-CK18 levels were all increased when the drug was used in combination with PTE-L, as compared to when LAP was used alone. In contrast, when CDDP and PTE-L were used in combination, no increase in these factors was observed (Figure 7C–F).




Figure 7. Effect of PTE on the antitumor effect of LAP and CDDP in a mouse tumor model. (A) Experimental protocol. TMK1 GC cells (1×10^7) were inoculated subcutaneously in mice. On day 1, LAP (40 mg/kg, ip) or CDDP (3 mg/kg, ip), with or without PTE (20 mg/kg, ip), was administered. On day 29, mice were euthanized. (B) Tumor volume on day 29, which was calculated according to the formula (minor axis² $\times$ major axis) / 2. * $p < 0.05$; PTE(−) vs. PTE(+). (C–F) Using whole-cell lysates of the tumors, the following parameters were measured using enzyme-linked immunosorbent assay: H₂O₂ (C), CHOP (D), nHIF1 α (E), and C-CK18 (F). * $p < 0.05$; PTE(−) vs. PTE(+). Error bar, standard deviation determined by the number of mice constituting each group. * Significance was calculated using ANOVA with Bonferroni correction. GC, gastric cancer; PTE, pterostilbene; C, no treatment; LAP, lapatinib; CDDP, cisplatin; CHOP, C/EBP homologous protein; nHIF, nuclear hypoxia-inducible factor; C-CK18, cleaved cytokeratin 18.

3. Discussion

In this study, we revealed that the combination of DOX or LAP with PTE-L inhibited the recruitment of the iron transporters mtNEET and ABCB8 to PDZD8, thereby causing the accumulation of mtFe and increasing mitochondrial ROS production. This resulted in HIF1 α activation, which further induced ER stress and induced apoptosis.

In this study, PTE induced apoptosis in GC cells either when used alone at high concentrations (Figure 1) or when used at lower concentrations in combination with mtFe-accumulating anticancer drugs (Figure 4). The associated mechanisms included increased *BAX* and decreased *BCL2* expression [17–19], activation of c-Jun N-terminal kinase and p38 pathways [20,21], and further inhibition of the receptors for advanced glycation end-product/signal transducer and activator of transcription 3 and AKT/mechanistic target of rapamycin pathways [22]. In our study, a decrease in *BCL2* and an increase in *BAX* expression levels played important roles in PTE-H, whereas the combination of PTE-H and mtFe-depositing anticancer drugs did not induce ER stress-induced apoptosis.

We found that DOX, LAP, and PTE led to mtFe accumulation (Figure 2). DOX has been investigated as an anticancer drug known to accumulate mtFe. LAP is an anticancer drug used for HER2-positive GC, and 5FU and CDDP were investigated as anticancer drugs that are frequently used for GC. DOX results in the accumulation of mtFe and ROS production [13]. In contrast, the iron transporter ABCB8 reduces mtFe- and DOX-induced toxicity [13]. However, there have been no studies on the effects of LAP, 5FU, and CDDP on mtFe accumulation.

SUN is a small molecule and a multitarget receptor tyrosine kinase inhibitor that mimics ATP and suppresses the phosphorylation of AKT and extracellular signal-regulated kinase (ERK), which are located downstream of the signal transduction pathway mediated by SUN, epithelial growth factor receptor, and HER2. We previously reported that SUN suppresses PDZD8 expression, leading to mtFe accumulation [12]. The original molecular targets and mechanisms of LAP, which inhibit intracellular signal transduction, are different from those of SUN. However, LAP, SUN, and DOX suppress PDZD8 as off-targets [12]. PDZD8 in the MAM anchors the ER and mitochondria bringing the two types of organelles in close proximity, facilitating material exchange between them [13]. Specifically, PDZD8 transfers calcium ions and lipids between the ER and mitochondria [23,24].

Our data showed that the iron-sulfur cluster transporter mtNEET [25,26] and iron transporter ABCB8 [27,28] were associated with PDZD8 (Figure 5). This suggested that both iron transporters bind to PDZD8 and are located within the MAM, transporting iron between the mitochondria and ER. *PDZD8* knockdown resulted in mtFe accumulation, similar to that observed with SUN, supporting the above considerations [12]. However, the mechanism through which these drugs suppress PDZD8 expression remains unclear and requires further investigation.

Our data showed that the combined use of DOX or LAP with PTE-L induced stronger mitochondrial ROS generation than did DOX or LAP alone (Figure 3). This was accompanied by increased expression of HIF1 α . The combination of PTE-L with DOX or LAP resulted in synergistic mtFe accumulation in GC cell lines. However, iron chelation with DFO did not reverse the cell death rate. This suggested that the retention of mtFe induced mitochondrial ROS production. Furthermore, we observed no change in mitochondrial oxidized lipids (mt-4HNE) and GPX4, which plays an important role in mitochondrial redox and negates the involvement of ferroptosis. Our data showed that the combination of PTE-L with DOX or LAP induced ER stress. During ER stress, the calcium-enhanced ER release generates mitochondrial ROS that are associated with MAM dysfunction [29]. This suggested that the increase in mitochondrial ROS levels caused by PTE-L involved crosstalk with ER stress.

Mitochondrial ROS are known to lead to HIF1 α accumulation and activation [30,31]. Mitochondrial ROS binds to the mitochondrial electron transport chain complex III and HIF1 α and stabilizes HIF1 α protein [32]. This is supported by the fact that the knockdown of Rieske's iron-sulfur protein of mitochondrial complex III prevents HIF1 α protein sta-

bilization [33]. Consequently, the invasive ability of cancer cells was reduced [34]. The hydroxyl radicals ($\cdot\text{OH}$) generated by the iron-dependent Fenton reaction, not only in the mitochondria but also in the perinuclear ER, promote *HIF1A* expression [35]. Thus, increased oxidative stress promotes the expression, stabilization, and activation of HIF1 α through a mechanism different from that of hypoxia.

In this study, ER stress was induced by the combination of PTE-L and anticancer drugs that accumulated mtFe (Figures 2 and 6). PTE alone is a potent inducer of ER stress [36] and causes ER stress through imbalances in redox homeostasis [37]. Overexpression of HIF1 α increases the transcription factor activity of the unfolded protein response pathway and CHOP expression, leading to ER stress [38]. This suggests that the combined use of PTE and anticancer drugs that cause the accumulation of mtFe induces ER stress by increasing mitochondrial ROS generation due to the mtFe accumulation, thereby upregulating and activating HIF1 α .

In our study, ER stress and apoptosis inhibitors inhibited cell death caused by the combined use of PTE-L, DOX, and LAP (Figure 4). Sustained ER stress caused apoptosis due to maladaptation to ER stress [38–40]. The mechanism may involve the fact that the ER stress sensor PERK aggregates at the MAM and mediates ROS signals between the ER and mitochondria [16]. The activation of PERK by unfolded proteins in the ER leads to the phosphorylation of the eukaryotic translation initiation factor 2 α [41], which induces the activation of CHOP, GADD34, and ATF3 and promotes the transcription of the relevant target genes [42–44]. PERK, thus, mediates apoptotic signals from CHOP [45]. Our data also suggest that the inhibition of HIF1 α and PERK suppresses apoptosis, leading to apoptosis due to ER stress (Figure 6).

LAP, which exhibited a synergistic effect with PTE-L in the present study, is a second-line treatment for HER2-positive GC [46]. Moreover, SUN, which has previously been reported to have a synergistic effect with PTE, has no indications for GC. The present study suggests that drugs that cause mtFe accumulation may exert antitumor effects when used in combination with PTE. This indicates that LAP and SUN may be more widely applicable when used in combination with PTE. Although the total dose of DOX is limited due to its cardiotoxicity [47], combining it with PTE makes it possible to obtain antitumor effects at lower doses. This may delay the onset of the side effects of DOX.

In the future, by investigating the mtFe accumulation effect of anticancer drugs, it may be possible to identify drugs whose antitumor effect will be enhanced when combined with PTE.

4. Materials and Methods

4.1. Cell Lines and Reagents

Human gastric carcinoma cell lines TMK1 (poorly differentiated adenocarcinoma) and MKN74 (well-differentiated adenocarcinoma) were gifts from Professor Wataru Yasui (Molecular Pathology, Hiroshima University, Hiroshima, Japan) [48–50]. The human monocytic cell line U937 was purchased from Dainihon Pharmacy Co. (Tokyo, Japan). TMK1 and MKN74 cells were cultured in Dulbecco's modified Eagle's medium (Wako Pure Chemical Corporation, Osaka, Japan) supplemented with 10% fetal bovine serum (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) at 37 °C in 5% CO₂.

LAP, DOX, 5FU, CDDP (Wako), and PTE (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan), echinomycin (HIF1 α inhibitor, Abcam, Cambridge, UK), and GSK2656157 (PERK inhibitor, Selleck, Houston, TX, USA) were purchased. The cells were incubated for 48 h. The IC₂₀s of the anticancer drugs were as follows: DOX, 0.13 and 0.1 μM ; 7.8 and 8.0 μM ; 5FU, 30 and 55 μM ; CDDP, 2.0 and 2.3 μM in TMK1 and MKN74, respectively.

4.2. Cell Growth and Apoptosis

Cell growth was assessed using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-based Celltiter 96 aqueous one-solution cell proliferation assay kit (Promega Corporation, Madison, WI, USA), as previously described [10].

Absorbance was measured at 490 nm on a Multiskan FC Microplate Photometer (Thermo Fisher Scientific, Waltham, MA, USA).

4.3. Reverse Transcription–Polymerase Chain Reaction

Reverse transcription–polymerase chain reaction (RT-PCR) was performed with 0.5 µg total RNA extracted from the three cell lines using the RNeasy kit (Qiagen, Germantown, MD, USA) to assess human and murine mRNA expressions. The primer sets used are listed in Table 1 and were synthesized by Sigma Genosys (St. Louis, MO, USA). The PCR products were electrophoresed on a 2% agarose gel and were stained with ethidium bromide. *ACTB* mRNA was amplified as the internal control.

Table 1. Primer sets, antibodies, and ELISA kits.

Primer Set			
Gene symbol	Gene bank ID	Forward primer (5′–3′)	Reverse primer (5′–3′)
BCL2	M13994.1	acgacaaccgggagatagtg	catcccagcctccgttatcc
BAX	L22473.1	catgaagacaggggcccttt	cttcagatggtagcgagg
GADD45	M60974.1	ggaggaattctcggctggag	tccatgtagcgactttcccg
CHOP	NM_001195053.1	ccagccactccccattatcc	ttcggtaatcagagctcgg
PDZD8	NM_173791.4	tctcgtgttgatgctgaag	ttgtctgacgtgttgggtgt
mitoNEET (CISD1)	BC007043.1	tccagaagacaacccaag	gcccacattgtctccagtct
ABCB8	NM_001282291.2	cgtggggtctcgtttaact	cctgacactggcgagacaat
HIF1α	AF208487.1	gaaagcgcaagtctcaaag	tgggtaggagatggagatgc
PERK	NM_004836.7	gcagaggcagtgaggttct	ggcaaagggtatgggagtt
ACTB	NM_001101.3	ggacttcgagcaagagatgg	agcactgtgttggcgtagac
Antibody			
Protein	Clone	Company	
PARP	-	GeneTex, Irvine, CA, USA	
mitoNEET	L70G2	Biocompare, South San Francisco, CA, USA	
ABCB8	F-4	Santa Cruz, Santa Cruz, CA, USA	
PDZD8	-	Bioss Inc, Woburn, MA, USA	
β-actin	-	Abcam, Cambridge, MA, USA	
ELISA			
Items	Catalog number	Company	
Hydrogen peroxide	21024	Aoxre Bioscience, Burlingane, CA, USA	
Human CHOP	LS-F8872	Lsbio, Shirley, MA, USA	
Human HIF1α	EHIF1A	Thermo Fisher, Tokyo, Japan	
4HNE	ab238538	Abcam, Cambridge, MA, USA	
Human GPX4	ARP-E4145	Biocompare, South San Francisco, CA, USA	
Cleaved CK18, M30	10011	VLVbio, Nacka, Sweden	

BCL2, B cell lymphoma 2; BAX, Bcl-2-associated X protein; GADD45, growth arrest and DNA damage inducible 45; CHOP, CCAAT/enhancer-binding protein homologous protein; mitoNEET, mitochondrial protein containing Asn–Glu–Glu–Thr (NEET) sequence; ABCB8, ATP-binding cassette subfamily B member 8; PDZD8, PDZ domain-containing 8; PARP, poly ADP-ribose polymerase; HIF, hypoxia-inducible factor; HNE4, mitochondrial hydroxynonenal-4; GPX4, glutathione peroxidase 4; CK18, cytokeratin 18.

4.4. Mitochondrial Imaging

Mitochondrial function was examined using fluorescent probes. Cells were incubated with the probes for 30 min at 37 °C and then imaged using a BZ-X710 All-in-One fluorescence microscope (KEYENCE, Osaka, Japan). We used dihydrorhodamine 123 (10 µM, Sigma) to assess oxidative stress, mitoGreen (100 nM, PromoCell GmbH, Heidelberg, Germany) to assess mitochondrial volume, tetrathylrhodamine ethyl ester (200 nM, Sigma) to assess mitochondrial membrane potential, and mitoFerrogreen (20 nM, Dojindo, Kumamoto, Japan) to assess mtFe.

4.5. Immunoblot Analysis

To prepare whole-cell lysates, cells were washed twice with cold phosphate-buffered saline (PBS), harvested, and lysed with RIPA buffer containing 0.1% sodium dodecyl sulfate (SDS) (Thermo Fisher) [51]. The Minute Cytoplasmic and Nuclear Extraction Kit (Invent Biotechnologies, Inc., Plymouth, MN, USA) was used to extract the nuclear and cytosolic fractions of the cells. Protein assays were performed using the Protein Assay Rapid Kit (Wako). Lysates (20 µg) were subjected to immunoblot analysis by using 12.5% SDS-polyacrylamide gel electrophoresis, followed by electrotransfer onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). The membranes were incubated with primary antibodies and peroxidase-conjugated IgG secondary antibodies (MBL, Nagoya, Japan). Protein expression was assessed using primary antibodies (Table 1). β -actin antibody (Abcam, Cambridge, MA, USA) was used to assess protein loading. Immune complex binding was visualized using a CSA system (DAKO, Carpinteria, CA, USA).

4.6. Immunoprecipitation

Immunoprecipitation was performed according to a previously described method [52]. The lysates were pre-cleaned in a lysis buffer containing protein A/G agarose (Santa Cruz Biotechnology) for 1 h at 4 °C and subsequently centrifuged. The supernatants were then incubated with a precipitation antibody against PDZD8 (Bios Inc., Woburn, MA, USA) and protein A/G agarose for 1.5 h at 4 °C. Precipitates were collected through centrifugation, washed three times with wash buffer, and solubilized in 4× Laemmli sample buffer (Bio-Rad) and 2-mercaptoethanol (Sigma). Immunoblotting was performed using antibodies against mitoNEET and ABCB8 (Table 1). VerBlot for IP Detection Reagent HRP (Abcam) was used as the secondary antibody.

4.7. Enzyme-Linked Immunosorbent Assay

Enzyme-linked immunosorbent assay (ELISA) kits were used to measure the concentrations of hydrogen peroxide, human CHOP, human HIF1 α , 4HNE, human GPX4, and cleaved CK18 (Table 1). The assay was performed using whole-cell lysates according to the manufacturer's instructions. A brief description is as follows. A total of 50 µL (10 µg) of protein sample was added to the wells and incubated at room temperature for 2 h; then, the solution was discarded. Each well was washed four times with the attached washing solution. A total of 100 µL of diluted detection antibody was added to the wells and incubated for 1 h at room temperature before the solution was discarded. After washing the wells four times, 100 µL of diluted horse radish peroxidase conjugate was added to each well and incubated for 30 min at room temperature. After discarding the solution, the wells were washed four times. A total of 100 µL of chromogenic substrate was added to each well and reacted for 30 min in the dark, and 100 µL of a stop solution was added. Immediately after stopping the reaction, the absorbance of each well was measured.

4.8. Animals

Four-week-old male BALB/c Slc-nu/nu mice were purchased from SLC Japan, Inc. (Shizuoka, Japan). The animals were maintained and subjected to experiments in accordance with the institutional guidelines approved by the Committee for Animal Experimentation of Nara Medical University and the current regulations and standards of the Ministry of Health, Labor, and Welfare of Japan (No. 13480, 18 May 2023 and No. 13480-1, 17 October 2023).

4.9. Animal Tumor Models

Subcutaneous murine tumor models were established by inoculating cancer cells (TMK-1: 1×10^7 per mouse) into the subcutaneous tissues of nude mice on day 0. For each cell line, 18 mice were randomly divided into five groups: Control, LAP alone, and LAP + PTE. LAP (40 mg/kg body weight, diluted with 5% dimethyl sulfoxide), CDDP (3 mg/kg body weight, diluted with 5% dimethyl sulfoxide), and PTE (20 mg/kg body

weight, diluted with 5% dimethyl sulfoxide) were administered intraperitoneally on day 1. Mice in the control group were injected with 100 μ L of PBS (Wako) into the intraperitoneal cavity. The tumor diameter was measured using calipers over the skin of each mouse on each treatment day. The mice were sacrificed on day 29, and the tumor tissues were subjected to ELISA.

4.10. Statistical Analysis

Statistical significance was calculated using analysis of variance (ANOVA) with InStat software (version 3.1; GraphPad, Los Angeles, CA, USA). Correlations were tested using Pearson's correlation coefficients. A two-sided p value of <0.05 was considered to indicate statistical significance.

Author Contributions: Study concept and design: H.K. Acquisition of data: Y.N., S.N., R.N., A.I. and R.S. Analysis and interpretation of data: Y.N., R.F.-T., S.M., R.O. and S.K. Technical support: Y.H. Supervision: H.S. and M.S. Drafting and editing of the manuscript: Y.N. and R.F.-T. Critical revision of the manuscript: R.F.-T. and H.K. All authors gave final approval of the version to be published and agree to be accountable for all aspects of the work. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by MEXT KAKENHI, Grant Numbers 22K16497 (Y.N.), 19K16564 (R.F.-T.), 23K19900 (R.O.), and 20K21659 (H.K.).

Institutional Review Board Statement: Animals were maintained and subjected to experiments in accordance with the institutional guidelines approved by the Committee for Animal Experimentation of Nara Medical University and the current regulations and standards of the Ministry of Health, Labor, and Welfare of Japan (No. 13480, 18 May 2023 and No. 13480-1, 17 October 2023).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article.

Acknowledgments: The authors thank Tomomi Masutani for expert assistance with the preparation of this manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviation

GC: gastric cancer; PTE, pterostilbene; mtFe, mitochondrial iron (II); 5FU, 5-fluorouracil; CDDP, Cisplatin; DOX, doxorubicin; LAP, lapatinib; MAM, mitochondria-associated endoplasmic reticulum membrane; PDZD8, PDZ domain-containing 8; HER2, human epidermal growth factor receptor 2; SUN, sunitinib; ER, endoplasmic reticulum; FER, ferostatin; DFO, deferoxamine; NAC, N-acetylcysteine; 4PBA, 4-phenylbutyric acid; PARP, poly[ADP-ribose] polymerase; GADD45, DNA damage-inducible; CHOP, CCAAT/enhancer-binding protein homologous protein; mitoNEET, mitochondrial protein containing the Asn-Glu-Glu-Thr (NEET) sequence; ABCB8, ATP-binding cassette subfamily B member 8; GPX, glutathione peroxidase; HIF, hypoxia-inducible factor; PERK, RNA-dependent protein kinase (PKR)-like ER kinase; ROS, reactive oxygen species; C-CK18, cleaved cytokeratin 18.

References

1. Statistics Bureau Ministry of Internal Affairs and Communications Japan. *Statistical Handbook of Japan 2017*; Statistics Bureau Ministry of Internal Affairs and Communications Japan: Tokyo, Japan, 2017. Available online: <https://www.stat.go.jp/english/data/handbook/pdf/2017all.pdf> (accessed on 7 December 2023).
2. International Agency for Research on Cancer. Globocan 2018 Latest Global Cancer Data. Available online: <https://www.iarc.who.int/infographics/globocan-2018-latest-global-cancer-data/> (accessed on 7 December 2023).
3. Mikami, H.; Nagase, H. Cancer Survival Rates at Japanese Association of Clinical Cancer Centers. Available online: <https://kapweb.chiba-cancer-registry.org/> (accessed on 8 December 2023).
4. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. *Gastric Cancer* **2011**, *14*, 101–112. [CrossRef] [PubMed]

5. Palmer, A.C.; Sorger, P.K. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. *Cell* **2017**, *171*, 1678–1691.e13. [[CrossRef](#)] [[PubMed](#)]
6. Bang, Y.J.; Van Cutsem, E.; Feyereislova, A.; Chung, H.C.; Shen, L.; Sawaki, A.; Lordick, F.; Ohtsu, A.; Omuro, Y.; Satoh, T.; et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. *Lancet* **2010**, *376*, 687–697. [[CrossRef](#)] [[PubMed](#)]
7. Zhang, X.L.; Yang, Y.S.; Xu, D.P.; Qu, J.H.; Guo, M.Z.; Gong, Y.; Huang, J. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. *World J. Surg.* **2009**, *33*, 2112–2118. [[CrossRef](#)] [[PubMed](#)]
8. Daniel, M.; Tollefsbol, T.O. Pterostilbene down-regulates hTERT at physiological concentrations in breast cancer cells: Potentially through the inhibition of cMyc. *J. Cell Biochem.* **2018**, *119*, 3326–3337. [[CrossRef](#)] [[PubMed](#)]
9. Hong Bin, W.; Da, L.H.; Xue, Y.; Jing, B. Pterostilbene (3',5'-dimethoxy-resveratrol) exerts potent antitumor effects in HeLa human cervical cancer cells via disruption of mitochondrial membrane potential, apoptosis induction and targeting m-TOR/PI3K/Akt signalling pathway. *J. BUON* **2018**, *23*, 1384–1389. [[PubMed](#)]
10. Moon, D.; McCormack, D.; McDonald, D.; McFadden, D. Pterostilbene induces mitochondrially derived apoptosis in breast cancer cells in vitro. *J. Surg. Res.* **2013**, *180*, 208–215. [[CrossRef](#)]
11. Mori, S.; Kishi, S.; Honoki, K.; Fujiwara-Tani, R.; Moriguchi, T.; Sasaki, T.; Fujii, K.; Tsukamoto, S.; Fujii, H.; Kido, A.; et al. Anti-Stem Cell Property of Pterostilbene in Gastrointestinal Cancer Cells. *Int. J. Mol. Sci.* **2020**, *21*, 9347. [[CrossRef](#)]
12. Hojo, Y.; Kishi, S.; Mori, S.; Fujiwara-Tani, R.; Sasaki, T.; Fujii, K.; Nishiguchi, Y.; Nakashima, C.; Luo, Y.; Shinohara, H.; et al. Sunitinib and Pterostilbene Combination Treatment Exerts Antitumor Effects in Gastric Cancer via Suppression of PDZD8. *Int. J. Mol. Sci.* **2022**, *23*, 4002. [[CrossRef](#)]
13. Roemhild, K.; von Maltzahn, F.; Weiskirchen, R.; Knüchel, R.; von Stillfried, S.; Lammers, T. Iron metabolism: Pathophysiology and pharmacology. *Trends Pharmacol. Sci.* **2021**, *42*, 640–656. [[CrossRef](#)]
14. Wang, R.; Hussain, A.; Guo, Q.Q.; Jin, X.W.; Wang, M.M. Oxygen and Iron Availability Shapes Metabolic Adaptations of Cancer Cells. *World J. Oncol.* **2024**, *15*, 28–37. [[CrossRef](#)] [[PubMed](#)]
15. Ichikawa, Y.; Ghanefar, M.; Bayeva, M.; Wu, R.; Khechaduri, A.; Naga Prasad, S.V.; Mutharasan, R.K.; Naik, T.J.; Ardehali, H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *J. Clin. Investig.* **2014**, *124*, 617–630. [[CrossRef](#)] [[PubMed](#)]
16. Verfaillie, T.; Rubio, N.; Garg, A.D.; Bultynck, G.; Rizzuto, R.; Decuypere, J.P.; Piette, J.; Linehan, C.; Gupta, S.; Samali, A.; et al. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. *Cell Death Differ.* **2012**, *19*, 1880–1891. [[CrossRef](#)] [[PubMed](#)]
17. Tan, K.T.; Chen, P.W.; Li, S.; Ke, T.M.; Lin, S.H.; Yang, C.C. Pterostilbene inhibits lung squamous cell carcinoma growth in vitro and in vivo by inducing S phase arrest and apoptosis. *Oncol. Lett.* **2019**, *18*, 1631–1640. [[CrossRef](#)] [[PubMed](#)]
18. Elsherbini, A.M.; Sheweita, S.A.; Sultan, A.S. Pterostilbene as a Phytochemical Compound Induces Signaling Pathways Involved in the Apoptosis and Death of Mutant P53-Breast Cancer Cell Lines. *Nutr. Cancer* **2021**, *73*, 1976–1984. [[CrossRef](#)] [[PubMed](#)]
19. Shin, H.J.; Han, J.M.; Choi, Y.S.; Jung, H.J. Pterostilbene Suppresses both Cancer Cells and Cancer Stem-Like Cells in Cervical Cancer with Superior Bioavailability to Resveratrol. *Molecules* **2020**, *25*, 228. [[CrossRef](#)] [[PubMed](#)]
20. Gao, H.; Liu, Z.; Xu, W.; Wang, Q.; Zhang, C.; Ding, Y.; Nie, W.; Lai, J.; Chen, Y.; Huang, H. Pterostilbene promotes mitochondrial apoptosis and inhibits proliferation in glioma cells. *Sci. Rep.* **2021**, *11*, 6381. [[CrossRef](#)] [[PubMed](#)]
21. Kong, Y.; Chen, G.; Xu, Z.; Yang, G.; Li, B.; Wu, X.; Xiao, W.; Xie, B.; Hu, L.; Sun, X.; et al. Pterostilbene induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells. *Sci. Rep.* **2016**, *6*, 37417. [[CrossRef](#)]
22. Chen, R.J.; Lyu, Y.J.; Chen, Y.Y.; Lee, Y.C.; Pan, M.H.; Ho, Y.S.; Wang, Y.J. Chloroquine Potentiates the Anticancer Effect of Pterostilbene on Pancreatic Cancer by Inhibiting Autophagy and Downregulating the RAGE/STAT3 Pathway. *Molecules* **2021**, *26*, 6741. [[CrossRef](#)]
23. Hirabayashi, Y.; Kwon, S.K.; Paek, H.; Pernice, W.M.; Paul, M.A.; Lee, J.; Erfani, P.; Raczkowski, A.; Petrey, D.S.; Pon, L.A.; et al. ER-mitochondria tethering by PDZD8 regulates Ca²⁺ dynamics in mammalian neurons. *Science* **2017**, *358*, 623–630. [[CrossRef](#)]
24. Gao, Y.; Xiong, J.; Chu, Q.Z.; Ji, W.K. PDZD8-mediated lipid transfer at contacts between the ER and late endosomes/lysosomes is required for neurite outgrowth. *J. Cell Sci.* **2022**, *135*, jcs255026. [[CrossRef](#)]
25. Lipper, C.H.; Stofleth, J.T.; Bai, F.; Sohn, Y.S.; Roy, S.; Mittler, R.; Nechushtai, R.; Onuchic, J.N.; Jennings, P.A. Redox-dependent gating of VDAC by mitoNEET. *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 19924–19929. [[CrossRef](#)]
26. Tan, G.; Liu, D.; Pan, F.; Zhao, J.; Li, T.; Ma, Y.; Shen, B.; Lyu, J. His-87 ligand in mitoNEET is crucial for the transfer of iron sulfur clusters from mitochondria to cytosolic aconitase. *Biochem. Biophys. Res. Commun.* **2016**, *470*, 226–232. [[CrossRef](#)]
27. Chang, H.C.; Shapiro, J.S.; Jiang, X.; Senyei, G.; Sato, T.; Geier, J.; Sawicki, K.T.; Ardehali, H. Augmenter of liver regeneration regulates cellular iron homeostasis by modulating mitochondrial transport of ATP-binding cassette B8. *eLife* **2021**, *10*, e65158. [[CrossRef](#)] [[PubMed](#)]
28. Issitt, T.; Bosseboeuf, E.; De Winter, N.; Dufton, N.; Gestri, G.; Senatore, V.; Chikh, A.; Randi, A.M.; Raimondi, C. Neuropilin-1 Controls Endothelial Homeostasis by Regulating Mitochondrial Function and Iron-Dependent Oxidative Stress. *iScience* **2019**, *11*, 205–223. [[CrossRef](#)] [[PubMed](#)]
29. Lin, Y.; Jiang, M.; Chen, W.; Zhao, T.; Wei, Y. Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response. *Biomed. Pharmacother.* **2019**, *118*, 109249. [[CrossRef](#)]

30. Patten, D.A.; Lafleur, V.N.; Robitaille, G.A.; Chan, D.A.; Giaccia, A.J.; Richard, D.E. Hypoxia-inducible factor-1 activation in nonhypoxic conditions: The essential role of mitochondrial-derived reactive oxygen species. *Mol. Biol. Cell* **2010**, *21*, 3247–3257. [\[CrossRef\]](#) [\[PubMed\]](#)
31. Emerling, B.M.; Plataniias, L.C.; Black, E.; Nebreda, A.R.; Davis, R.J.; Chandel, N.S. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. *Mol. Cell Biol.* **2005**, *25*, 4853–4862. [\[CrossRef\]](#)
32. Guzy, R.D.; Hoyos, B.; Robin, E.; Chen, H.; Liu, L.; Mansfield, K.D.; Simon, M.C.; Hammerling, U.; Schumacker, P.T. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. *Cell Metab.* **2005**, *1*, 401–408. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Brunelle, J.K.; Bell, E.L.; Quesada, N.M.; Vercauteren, K.; Tiranti, V.; Zeviani, M.; Scarpulla, R.C.; Chandel, N.S. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. *Cell Metab.* **2005**, *1*, 409–414. [\[CrossRef\]](#) [\[PubMed\]](#)
34. Wang, F.; Zhang, R.; Xia, T.; Hsu, E.; Cai, Y.; Gu, Z.; Hankinson, O. Inhibitory effects of nitric oxide on invasion of human cancer cells. *Cancer Lett.* **2007**, *257*, 274–282. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Liu, Q.; Berchner-Pfannschmidt, U.; Möller, U.; Brecht, M.; Wotzlaw, C.; Acker, H.; Jungermann, K.; Kietzmann, T. A Fenton reaction at the endoplasmic reticulum is involved in the redox control of hypoxia-inducible gene expression. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 4302–4307. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Papandreou, I.; Verras, M.; McNeil, B.; Koong, A.C.; Denko, N.C. Plant stilbenes induce endoplasmic reticulum stress and their anti-cancer activity can be enhanced by inhibitors of autophagy. *Exp. Cell Res.* **2015**, *339*, 147–153. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Zhang, B.; Wang, X.Q.; Chen, H.Y.; Liu, B.H. Involvement of the Nrf2 pathway in the regulation of pterostilbene-induced apoptosis in HeLa cells via ER stress. *J. Pharmacol. Sci.* **2014**, *126*, 216–229. [\[CrossRef\]](#)
38. Delbrel, E.; Soumare, A.; Naguez, A.; Label, R.; Bernard, O.; Bruhat, A.; Fafournoux, P.; Tremblais, G.; Marchant, D.; Gille, T.; et al. HIF-1 α triggers ER stress and CHOP-mediated apoptosis in alveolar epithelial cells, a key event in pulmonary fibrosis. *Sci. Rep.* **2018**, *8*, 17939. [\[CrossRef\]](#)
39. Hetz, C. The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. *Nat. Rev. Mol. Cell Biol.* **2012**, *13*, 89–102. [\[CrossRef\]](#)
40. Kim, C.; Kim, B. Anti-Cancer Natural Products and Their Bioactive Compounds Inducing ER Stress-Mediated Apoptosis: A Review. *Nutrients* **2018**, *10*, 1021. [\[CrossRef\]](#)
41. Korennykh, A.; Walter, P. Structural basis of the unfolded protein response. *Annu. Rev. Cell Dev. Biol.* **2012**, *28*, 251–277. [\[CrossRef\]](#)
42. Sano, R.; Reed, J.C. ER stress-induced cell death mechanisms. *Biochim. Biophys. Acta* **2013**, *1833*, 3460–3470. [\[CrossRef\]](#)
43. Michel, S.; Canonne, M.; Arnould, T.; Renard, P. Inhibition of mitochondrial genome expression triggers the activation of CHOP-10 by a cell signaling dependent on the integrated stress response but not the mitochondrial unfolded protein response. *Mitochondrion* **2015**, *21*, 58–68. [\[CrossRef\]](#)
44. Han, J.; Back, S.H.; Hur, J.; Lin, Y.H.; Gildersleeve, R.; Shan, J.; Yuan, C.L.; Krokowski, D.; Wang, S.; Hatzoglou, M.; et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. *Nat. Cell Biol.* **2013**, *15*, 481–490. [\[CrossRef\]](#) [\[PubMed\]](#)
45. Oyadomari, S.; Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. *Cell Death Differ.* **2004**, *11*, 381–389. [\[CrossRef\]](#) [\[PubMed\]](#)
46. Oh, D.Y.; Bang, Y.J. HER2-targeted therapies—A role beyond breast cancer. *Nat. Rev. Clin. Oncol.* **2020**, *17*, 33–48. [\[CrossRef\]](#) [\[PubMed\]](#)
47. Chlebowski, R.T. Adriamycin (doxorubicin) cardiotoxicity: A review. *West. J. Med.* **1979**, *131*, 364–368. [\[PubMed\]](#)
48. Ochiai, A.; Yasui, W.; Tahara, E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. *Jpn. J. Cancer Res.* **1985**, *76*, 1064–1071. [\[PubMed\]](#)
49. Motoyama, T.; Hojo, H.; Watanabe, H. Comparison of seven cell lines derived from human gastric carcinomas. *Acta Pathol. Jpn.* **1986**, *36*, 65–83. [\[CrossRef\]](#)
50. Yokozaki, H. Molecular characteristics of eight gastric cancer cell lines established in Japan. *Pathol. Int.* **2000**, *50*, 767–777. [\[CrossRef\]](#)
51. Kuniyasu, H.; Oue, N.; Wakikawa, A.; Shigeishi, H.; Matsutani, N.; Kuraoka, K.; Ito, R.; Yokozaki, H.; Yasui, W. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. *J. Pathol.* **2002**, *196*, 163–170. [\[CrossRef\]](#)
52. Kuniyasu, H.; Yasui, W.; Pettaway, C.A.; Yano, S.; Oue, N.; Tahara, E.; Fidler, I.J. Interferon-alpha prevents selection of doxorubicin-resistant undifferentiated-androgen-insensitive metastatic human prostate cancer cells. *Prostate* **2001**, *49*, 19–29. [\[CrossRef\]](#)

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.